Mucin Concentration in Sputum From COPD Patients During a Pulmonary Exacerbation (mucinCOPDex)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01848093|
Recruitment Status : Withdrawn
First Posted : May 7, 2013
Last Update Posted : November 15, 2016
chronic obstructive pulmonary disease (COPD) is typically associated with mucus hypersecretion in the airways. In health, mucin is the major macromolecular component and is responsible for the protective and clearance properties of the mucus gel. In a recent study the investigators found that mucins are decreased and unstable in the sputum of adult cystic fibrosis (CF) patients.
In this study the investigators want to investigate the differences on the mucin quantity and quality of airway secretions during pulmonary exacerbation of patients with COPD.
|Condition or disease||Intervention/treatment|
|COPD||Other: sputum collection|
We hypothesize that during an exacerbation the mucin amount is increasing.
The aim of this study is to evaluate the molecular (mucins) and structure properties (mucin-stability) of the airway secretions in COPD related to the severity of the disease.
We characterize sputum composition of patients with pulmonary exacerbations. Using gel electrophoresis, with specific antibodies we will analyze MUC5AC and MUC5B mucins.
The significance of these studies is that they will give us novel information about the pathogenesis of chronic inflammatory airway diseases, provide tools for assessing the progression of lung disease, and most critically, will identify novel opportunities and targets for therapeutic intervention.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Molekularbiologische Eigenschaften Des Sputums während Einer Pulmonalen COPD Exacerbation|
|Study Start Date :||December 2008|
|Actual Primary Completion Date :||June 2013|
|Actual Study Completion Date :||July 2013|
COPD Stadium 2 and 3 during pulmonary exacerbation
Other: sputum collection
collecting of spontaneous sputum from the patient
- mucin concentration [ Time Frame: 2 month ]analyzing mucin concentration by western
- mucin stability [ Time Frame: 2 month ]analyzing mucin stability at 37C over 24 hours
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01848093
|pulmonary department, University Marburg|
|Marburg, Germany, 35043|
|Principal Investigator:||Markus Henke, MD||University Marburg|